Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Surviving rare ovarian cancer: what comes next? new study investigates Long-Term fatigue and health

NCT ID NCT03418844

Knowledge-focused Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at women who have recovered from rare ovarian cancers (germ cell or sex cord-stromal tumors) to understand how the disease and chemotherapy affect their lives years later. Researchers will use questionnaires to measure chronic fatigue, quality of life, and other issues, and will also perform heart, lung, and hearing tests. The goal is to learn about the long-term side effects of treatment so doctors can better support survivors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how rare ovarian cancer and its treatments affect women's long-term health and daily life, guiding better follow-up care.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 268 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2018

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age\> 18 years; * Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally; * Patient who has had surgery and chemotherapy (interest group) or only a surgery (control group); * Patient in remission more than 2 years after the end of the initial treatment; * Relapse authorized if remission more than 2 years after the end of the treatment; * Patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix); * Patient having signed his consent to participate Exclusion Criteria: * Pregnant or breastfeeding woman; * Psychiatric pathology that may disrupt the course of the study or prevent the interpretation of results; * Person deprived of liberty; * Major subject to a legal protection measure or unable to express his consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Germ cell tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

germ cell tumor malignant germ cell tumor of ovary malignant non-epithelial tumor of ovary Neoplasms, Germ Cell and Embryonal ovarian sex cord-stromal tumor Sex Cord-Gonadal Stromal Tumors sex cord-stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Germ cell tumor Malignant non-epithelial ovarian tumors Sex cord-stromal tumor

Contacts and locations

Locations

  • CH Fleyriat

    Bourg-en-Bresse, France

  • CHRU Stasbourg Hôpital Civil

    Strasbourg, France

  • CHU Besançon Jean MINJOZ

    Besançon, France

  • CHU Poitiers

    Poitiers, France

  • Centre Catherine de Sienne

    Nantes, France

  • Centre François Baclesse

    Caen, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Léon Berard

    Lyon, France

  • Centre Paul Papin

    Angers, France

  • GH Cochin Broca Hôtel-Dieu

    Paris, France

  • HEGP

    Paris, Paris, France

  • Hôpital Diaconesses-Croix St Simon

    Paris, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Curie,

    Paris, France

  • Institut Gustave Roussy

    Paris, France

  • Institut Jean Godinot

    Reims, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut Rennais de Cancérologie

    Rennes, France

  • Institut de Cancérologie de l'Ouest

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.